Press Releases

 
Press Releases
  Date Title and Summary View
Jan 25, 2018
FREMONT, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary ADAM technology, today announced the results of the special meeting of stockho...
Jan 3, 2018
FREMONT, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray ("ADAM") technology, today announced that it has ...
Dec 15, 2017
FREMONT, Calif., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, announced today that Bruce Steel has tendered his resignation f...
Nov 15, 2017
FREMONT, Calif., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray ("ADAM") technology, announced that ...
Nov 9, 2017
First patient enrolled in long term safety study in November 2017Phase 2/3 data presented at International Headache Society in SeptemberClinical results published in two leading scientific journalsAccess to capital expanded to fund Long-term Safety Study FR...
Nov 8, 2017
FREMONT, Calif., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray ("ADAM") technology, announced the i...
Nov 1, 2017
FREMONT, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray (ADAM) technology, today announced that it will host a conferen...
Oct 20, 2017
FREMONT, Calif., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, announced today that it has entered into a common stock purchas...
Oct 12, 2017
FREMONT, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray ("ADAM") technology, announced today...
Oct 4, 2017
FREMONT, Calif., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company"), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, announced today that Mr. Kenneth R. Greathouse has been appoin...
Page:
1
... NextLast
= add release to Briefcase